AXL and neoplasm: In summary, our IMC cohort provides mechanistic evidence that tAXL-upregulation and adverse mutations modulate the TME along an axis towards infiltrating, activated neutrophils and away from anti-tumor immune populations including CD4 and CD8 T-cells which associated with ICI survival, high PDL1 TPS, and AXL IC-positivity.